Healthcare

Joel Sendek is a Managing Director and Head of our Life Sciences Equity Research team.  Prior to joining Oppenheimer, Joel held CFO positions at four different biotech companies.  Prior to that Joel was a senior analyst covering biotechnology at Lazard and subsequently Stifel where he also served as head of the healthcare equity research group.  Joel has covered over 100 companies during the course of his sell-side career ranging from profitable large-caps to microcap biotech companies.  Joel has been recognized by The Wall Street Journal as an All-Star Analyst with a number one ranking for stock picking.  Earlier in his career he worked in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs.  He has a biochemistry degree from Rice University.

Matt Biegler is a Senior Analyst covering Emerging Biotechnology. Prior to joining Oppenheimer, Matt worked with Mark Breidenbach covering Biotechnology. Prior to his Wall Street career, Matt spent over five years in the healthcare industry, most recently as a Consultant at Parexel International, a Contract Research Organization. His areas of expertise include clinical trial design and strategy. Matt holds a Bachelor’s degree in Biochemistry and Molecular Biology from Boston University, and a Master’s in Biotechnology from the Columbia University Graduate School of Arts and Sciences.

François Brisebois is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, he was a Senior Research Analyst at Craig-Hallum Capital covering Biotechnology and Biopharmaceuticals. He previously worked at Laidlaw Capital Markets as a Senior Analyst covering Biotechnology and Specialty Pharmaceuticals and started his Wall Street career at healthcare specialty firm Summer Street Research Partners. Frank holds a Bachelor’s degree in Molecular Biology from Colgate University and a Master of Science in Pharmaceutical Sciences from University of Montreal.

Jeff Jones is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jeff founded and ran One Health Advisors, LLC which provided strategic advisory services for the human and animal biopharma sector. Prior to founding One Health, Jeff had served in numerous roles with biotechnology companies, including Vice President of Business Development at Aratana Therapeutics and COO at Pharmathene. Jeff received an B.A. in Biology from University of Virginia and a Ph.D. in Cell & Molecular Biology from Baylor College of Medicine. He has also completed an M.B.A. at Cornell University, Johnson Graduate School of Management.

Suraj Kalia is Managing Director and Senior Analyst covering Medical Technology and Devices. Previously, Suraj was Managing Director at Northland Securities. He has over 15 years of sell-side research experience and in 2018 was ranked #1 Healthcare Equipment & Supplies Analyst by Thomson Reuters. He has held senior equity research analyst positions at Rodman & Renshaw, Sanders Morris, Harris and Piper Jaffray. He also worked at Entegris Inc. in Business Development and at the University of St. Thomas in Minneapolis as an Adjunct Professor of Finance. Suraj holds a Bachelor’s degree in Technology Chemical Engineering from Indian Institute of Technology and a Master of Engineering in Chemical Engineering from Stevens Institute of Technology. He holds an M.B.A. from University of St. Thomas and the CFA certification.

Matt Nirenberg is an Executive Director and Senior Analyst covering Healthcare Services. He joined Oppenheimer in 2005 working with Michael Wiederhorn’s team, and continues to help Michael broaden his coverage.  Prior to Oppenheimer, he spent five years on the buy-side.  Matt earned an MBA in Finance and Accounting from NYU Stern and a BSBA from Washington University in St. Louis.   He holds the designation of Chartered Financial Analyst.